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Immunotherapy: new options in 
breast cancer treatment
Michael Untch†, Nina Ditsch and Kerstin Hermelink
Immunotherapy is a promising new approach in breast cancer treatment, complementing 
surgery, chemotherapy, radiation and antihormonal therapy. Primarily, two treatment 
options are available which are supported by a rapidly growing body of clinical evidence. 
These are active specific immunotherapy with Theratope® and passive immunotherapy 
targeting the HER-2 receptor with trastuzumab (Herceptin®). Trastuzumab has a proven 
efficacy as monotherapy as well as in combination with chemotherapeutic agents in 
HER-2-overexpressing metastatic breast cancer. Trastuzumab is generally well tolerated 
although cardiotoxicity has been observed, especially when in combination with 
doxorubicin (Adriamycin®), where this can be a serious concern. Therefore, less 
cardiotoxic combinations with docetaxel (Taxotere®), vinorelbine (Navelbine®) and 
epirubicin (Pharmorubicin®) or cyclophosphamide (Endoxana®) have been tested. The 
combination of trastuzumab with paclitaxel (Taxol®) is well approved. The use of 
trastuzumab in adjuvant and preoperative therapy is currently being examined in 
controlled trials. After a brief outline of immunotherapy with Theratope and trastuzumab, 
this article reviews recent and ongoing clinical studies conducted with trastuzumab.
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Active specific immunotherapy: Theratope®
The cancer vaccine Theratope® (Biomira Inc.,
Alberta, Canada) stimulates an immune
response against the tumor-associated antigen
Sialyl-Tn (STn), a carbohydrate that associates
with the mucin MUC1 overexpressed in breast
cancer cells. STn is associated with more
aggressive disease and poor prognosis. Theratope
consists of a synthetic STn antigen emulating
the tumor cell STn and a carrier molecule
which presents the antigen to the immune
effector cells, thus triggering antiSTn antibodies
as well as mucin-specific T-cell responses [1].
A Phase II study has tested Theratope in
metastatic breast cancer patients with STn
expression [2]. A significant survival benefit
could be demonstrated for patients treated with
a combination of intravenous cyclophosphamide
(Endoxana®, Baxter, IL, USA) and Theratope.
There was no correlation in the antibody
response to the carrier molecule and survival.
This led to the assumption that the observed
survival benefit is based upon the specific
antibody response to the synthetic mimic of the
STn carbohydrate incorporated in the Theratope
vaccine. A review of clinical trials conducted
with Theratope has been published [3].
Monoclonal antibodies against 
HER-2: trastuzumab
The HER-2/neu oncoprotein
HER-2 is a transmembrane tyrosine kinase
receptor belonging to the family of epidermal
growth factor receptors (FIGURE 1). It is encoded
by the HER-2/neu proto-oncogene located on
chromosome 17q21 [4]. HER-2 is overex-
pressed in approximately 25–30% of all breast
cancers [5]. Amplification of HER-2/neu gene
and overexpression of the HER-2 protein
stimulates cancer cell growth and is therefore
of high prognostic relevance.
HER-2 overexpression correlates with a
shorter relapse-free interval and overall survival
time [6]. The unfavorable prognosis associated
with HER-2 overexpression has been confirmed
by numerous studies [7].
HER-2 overexpression is determined by
immunohistochemistry. Currently, the most
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commonly used test is the HercepTest® (Genentech, CA,
USA), originally developed by Dako (Glostrup, Denmark)
using a polyclonal antibody against HER-2/neu. A HER-2
score of 0 and 1+ is classified as negative and 3+ is clearly posi-
tive. In the case of a HER-2 score of 2+ (marginally positive) a
fluorescence in situ hybridization (FISH) analysis should follow
for exact determination. Accurate determination of HER-2
status is an indispensable prerequisite to every trastuzumab
(Herceptin®, Genentech) treatment.
Therapy of HER-2-overexpressing breast cancer 
with trastuzumab
Trastuzumab is a monoclonal antibody (mAb) that targets the
extracellular domain of the HER-2 protein. The response to
therapy correlates with HER-2 overexpression. Trastuzumab is
indicated clearly in patients with immunohistochemical scores of
3+ or more. In case of a 2+ score, FISH analysis should clarify
amplification of the HER-2/neu gene [8–10].
In the USA, trastuzumab was approved for the treatment of
metastatic breast cancer in 1998 and European approval followed
in 2000. Phase II and III studies demonstrated efficacy and
tolerability of trastuzumab in metastatic breast cancer patients
with HER-2 overexpression (score 2+ and 3+). In these trials,
trastuzumab has been used either as monotherapy or in combi-
nation with various chemotherapeutic agents. The treatment
dose of trastuzumab is 2 mg/kg/week following a loading dose
of 4 mg/kg. A trastuzumab treatment regimen of 3-weekly
8 mg/kg loading dose followed by 6 mg/kg is also being tested.
Trastuzumab monotherapy
Cobleigh and colleagues treated 222 metastatic breast cancer
patients with trastuzumab as second- or third-line therapy
(68% had previously received chemotherapy) [11]. The overall
response rate was 15% (6% with a score of 2+, 18% with a
score of 3+) with a median time-to-progression of 9.1 months
and a median survival of 13 months. There were eight com-
plete responses (CRs) and 26 partial remissions (PRs). Of the
patients, 40% suffered mild toxicity and cardiac side effects were
observed in ten patients (4.7%), of which nine were pretreated
with doxorubicin (Adriamycin®, Pharmacia, NJ, USA).
Vogel and coworkers treated 114 metastatic breast cancer
patients with two different dosages of trastuzumab [12]. The
first group received a loading dose of 8 mg/kg and a 4 mg/kg
maintaining dose, while the second group received 4 mg/kg fol-
lowed by 2 mg/kg. Treatment was well tolerated in both treat-
ment groups. Toxicity was more pronounced in the dose-inten-
sified group but generally mild. The overall response rate was
26% without a significant difference between groups (24%
standard dose, 28% dose-intensified). Subgroup analysis dem-
onstrated an elevated response rate in immunohistochemistry
(3+, 35%) and in FISH-positive patients (41%). The median
survival was 24.4 months.
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Current data suggest that FISH analysis predicts the benefit
from trastuzumab therapy more accurately and selection of
patients should therefore be based upon this test [13]. Two
studies with trastuzumab monotherapy assessed correlations
of positive test results and therapy benefit. In the first study,
H0650g, patients were treated with trastuzumab as first
nonhormonal therapy for metastatic disease, and in the second,
H0649g, patients who displayed disease progression after one
or two previous chemotherapies were enroled. The correlation
of response rate and a positive FISH test result was 34%
(H0650g) and 19% (H0649g), compared with a correlation
with immunohistochemically determined HER-2 overexpres-
sion of only 26 and 15%, respectively (TABLE 1). If CR, PR
and stable disease (SD) are considered together, the differences
are similar.
Trastuzumab in combination therapies
First results of a treatment combining paclitaxel (90 mg/m2/week)
and trastuzumab were published in 1999 and the response rate
was 61% [14].
Slamon and colleagues compared the treatment effects of
chemotherapy alone versus chemotherapy and trastuzumab
combined in a sample of 469 patients with HER-2-overexpress-
ing tumors and without previous treatment for metastatic
breast cancer [15]. Patients were randomized to one of four
treatment regimens: 
• Trastuzumab plus an anthracycline and cyclophosphamide:
doxorubicin 60/600 mg/m2 or epirubicin 75/600 mg/m2 for
six doses every 3 weeks
• An anthracycline and cyclophosphamide alone
• Trastuzumab plus paclitaxel (Taxol®, Bristol-Myers Squibb,
NY, USA), 175 mg/m2 for six doses every 3 weeks
• Paclitaxel alone, 175 mg/m2 
The trial demonstrated favorable effects of trastuzumab on
response rate, median time-to-progression, median duration of
response and survival. Overall responses rates to chemotherapy
plus trastuzumab versus chemotherapy alone were 50 and 32%,
respectively, (p < 0.001). The combination therapy with anthra-
cycline chemotherapy plus trastuzumab demonstrated an
increased response rate of 56 versus 42% for the same chemo-
therapy regimen without trastuzumab (p = 0.02). Response rates
to trastuzumab plus paclitaxel versus paclitaxel alone were 41 and
17%, respectively, (p < 0.001). Both trastuzumab groups demon-
strated an improved time-to-progression compared with groups
receiving chemotherapy alone. Time-to-progression was 7.8
months for anthracycline/cyclophosphamide plus trastuzumab
versus 6.1 months for anthracycline/cyclophosphamide alone (p
< 0.001) and 6.9 months for paclitaxel plus trastuzumab versus
3.0 months for paclitaxel alone ( p < 0.001).
The median survival time of all 469 patients was 9.1 months
with trastuzumab versus 6.1 months without trastuzumab
(p < 0.001). For the different treatment arms, anthracy-
cline/cyclophosphamides plus trastuzumab was 9.1 months versus
6.7 months, (p = 0.005) and for paclitaxel plus trastuzumab was
10.5 months versus 4.5 months (p < 0.01). Trastuzumab there-
fore improved the median survival time by 4.8 months compared
with chemotherapy alone (p = 0.046).
Table 1. Results of the H0650 and H0649 studies determining HER-2 overexpression by fluorescence in situ 
hybridization and immunohistochemistry.
Trial parameters FISH + FISH- IHC+
H0650g
Response rate (%) 34 7 26
CR+PR+SD (%) 48 10 38
Overall survival (months) 24.5 24.4 24.4
H0649g
Response rate (%) 19 0 15
CR+PR+SD (%) 33 6 28
Overall response (months) 14.2 8.8 12.8
+: HER-2-positive; -: HER-2-negative; CR: Complete response; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemistry; PR: Partial response; SD: Stable disease.
Table 2. Response rate, clinical benefit and time-to-disease progression in correlation with HER-2 serum antigen [21].
Parameters HER-2/neu-positive HER-2/neu-negative Significance
Objective response rate (%) 15 31 p = 0.0001
Clinical benefit (%) 30 50 p = 0.0001
Time-to-progression (months) 4.2 9.2 p = 0.0001
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Symptomatic and asymptomatic cardiac dysfunctions were
observed in 63 patients. Of these, 16% who had been treated with
an anthracycline/cyclophosphamide and trastuzumab combina-
tion developed a New York Heart Association class III or IV dys-
function, 3% with anthracycline/cyclophosphamide alone, 2%
with paclitaxel and trastuzumab, and 1% with trastuzumab alone.
Two studies have researched combination therapy with
trastuzumab. The first is with vinorelbine (Navelbine®, Glaxo-
SmithKline, London, UK) and the second (M77003), is
with epirubicin/cyclophosphamide as first-line therapy in
anthracycline-naive metastatic breast cancer patients.
In the first study, 40 HER-2-positive patients with metastatic
disease received 25 mg/m2 vinorelbine every week with a load-
ing dose of 4 mg/kg trastuzumab [16]. Of the patients, 82% had
previous adjuvant (30%) or palliative (25%) therapy, 20% had
previously received anthracyclines, 15% taxanes and 38%
anthracyclines and taxanes. The overall response rate was 75%
and the combination therapy was well tolerated. The most
common hematological side effect was neutropenia and three
patients developed Grade 2 cardiotoxicity.
In the first part of Phase II of the second study, 26 HER-2/neu
patients were treated with 60/600 mg/m2 epirubicin/cyclo-
phosphamide for four doses, every 3 weeks, plus trastuzumab
every week until week 103, with an overall response of 71%. In
the second part, 25 Her-2/neu-positive patients were treated
with an elevated dose of 90/600 mg/m2 epirubicin/cyclophos-
phamide and trastuzumab for 103 weeks. HER-2/neu-negative
patients were treated as a control group (25 patients) with the
same dose for four doses every 3 weeks without trastuzumab. In
this study, cardiac function was monitored closely. A total of
eight patients had a left ventricular ejection fraction (LVEF)
decrease of more than 10%, however, no patients demonstrated
a decrease of more than 50%. No patients developed a sympto-
matic change of the LVEF [16]. In the subsequent and ongoing
Phase III study, 75 Her-2/neu positive patients are treated with
60/600 or 90/600 mg/m2 epirubicin/cyclophosphamide every
3 weeks followed by trastuzumab until progression. Additional
Her-2/neu neagative patients (75) will receive 90/600 mg/m2
epirubicin/cyclophosphamide. Results are not yet available. 
The efficacy of trastuzumab with paclitaxel is currently being
examined in the Cancer and Leukemia Group B (CALGB)
9840 study (weekly vs. 3-weekly trastuzumab plus paclitaxel).
Trastuzumab & antihormonal therapy
According to the results of several studies, HER-2/neu overex-
pression is associated with resistance to antihormonal therapy
[17]. The International Breast Cancer Study Group analyzed
the data of 1506 patients and found a correlation of HER-2
overexpression and negative hormone receptor (HR) status.
Both Borg and coworkers, and Ravdin and colleagues
reported a decreased effect of tamoxifen in HR-positive and
HER-2-overexpressing patients [18,19].
Mass and colleagues presented similar clinical results of estro-
gen receptor (ER)-negative, HER-2-positive, as well as ER-pos-
itive, HER-2-positive patients treated with trastuzumab alone
or in combination with chemotherapy [20].
Lipton and colleagues indicated that elevated HER-2 serum
antigen correlates with decreased efficacy and shorter survival
of breast cancer patients with metastatic disease treated with
tamoxifen compared with letrozole (Femara®, Novartis, Basel,
Switzerland) (TABLE 2) [21].
To investigate the relationship of HER-2 overexpression and
HR expression, HER-2, ER and progesterone receptors were
examined as continuous variables in 1359 breast cancer specimens
in 14 cell lines, some of which had been transfected with the
HER-2/neu gene [22]. Transfected cell lines expressed significantly
lower levels of ER and progesterone receptors than parental
lines. In two clinical cohorts, primary tumors with HER-2
overexpression or pathologic amplification in the nucleus had
significantly lower levels of ER and progesterone receptors than
patients without HER-2 overexpression or amplification.
Box 1. Ongoing trastuzumab studies. 
•  The National Surgical Adjuvant Breast Project trial B-31 
uses a 3-weekly anthracycline/cyclophosphamide 
treatment, for four cycles, followed by four cycles of 3-
weekly paclitaxel plus trastuzumab versus the same 
chemotherapy regimen without trastuzumab in node-
positive, HER-2-positive breast cancer patients. Over a 
period of 5 years, 2700 patients will be enrolled. To date, 
more than 1200 patients have been accrued.
•  The North Central Cancer Treatment Group trial N9831 is a 
randomized three-arm trial. Treatment with 3-weekly 
anthracycline/cyclophosphamide for four cycles in all three 
arms is followed by weekly paclitaxel for 12 cycles versus 
weekly paclitaxel for 12 cycles plus trastuzumab for 1 year 
versus weekly paclitaxel and trastuzumab for 12 cycles 
followed by 40 cycles of trastuzumab monotherapy. Patients 
have node-positive or high-risk node-negative breast cancer 
with overexpression of HER-2. To date, more than 1400 
patients have been recruited.
•  In the Breast Cancer International Research Group trial 006, 
patients with node-positive or high-risk node-negative, 
HER-2-overexpressing primary breast cancer are randomized 
to one of three treatment arms: four cycles of 3-weekly 
doxorubicin and cyclophosphamide, followed by either four 
cycles of 3-weekly docetaxel, four cycles of  3-weekly 
docetaxel plus trastuzumab for 1 year, or docetaxel plus 
carboplatin for six cycles, followed by trastuzumab for 1 year. 
The study has now accrued more than 1600 patients.
•  The HERceptin Adjuvant (HERA) study is a multicenter study 
in which patients with verified HER-2 overexpression are 
randomly assigned to three different treatment groups: 
trastuzumab 1 year, 3-weekly after optimal primary therapy, 
trastuzumab 2 years, 3-weekly after optimal primary therapy 
or optimal primary therapy only (surgery, radiotherapy or 
endocrine therapy).
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Therefore, pathologic HER-2 amplification and overexpression
seems to downregulate expression of ER and progesterone
receptors, thus impairing the efficacy of hormone therapy.
Trastuzumab in the adjuvant setting
A pilot study conducted in 40 Stage II and III breast cancer
patients with preoperative weekly trastuzumab and 3-weekly
paclitaxel, followed by surgery and adjuvant doxorubicin/cyclo-
phosphamide has achieved encouraging results. Clinical response
rate to preoperative therapy was 75% and complete pathologic
response was 18%. Therapy response was more probable for
patients with HER-2 3+ tumors (84%) than for patients with 2+
HER-2 status (38%). Only four patients developed Grade 2
cardiotoxicity, otherwise no serious toxicity was observed [23].
Presently, several trastuzumab trials are ongoing in the adjuvant
situation (BOX 1). To date, over 950 patients have been enrolled in
the HERceptin Adjuvant (HERA) trial and accrual is expected to
continue until 2004 and reach a total of 3192 women.
A Phase II preoperative study with epirubicin/cyclophospha-
mide followed by paclitaxel/trastuzumab followed by postoper-
ative therapy with trastuzumab in patients with HER-2 overex-
pressing primary breast cancer has begun (TECHNO trial, by
Untch M and coworkers) (FIGURE 2).
Expert opinion
Overexpression of the HER-2 protein is associated with
aggressive tumor growth and poor prognosis. Furthermore,
most patients with HER-2-overexpressing tumors benefit less
from antihormonal treatment alone compared with nonoverex-
pressing patients. Therefore, the additional therapy option pro-
vided by trastuzumab is important for this subgroup of breast
cancer patients at high risk of recurrence. Trastuzumab com-
bines high efficacy with a toxicity profile advantageous to most
patients. Except for cardiac toxicity, especially in patients who
have received anthracyclines, there are almost no harmful side
effects. Trastuzumab is currently approved for treatment of
metastatic breast cancer and has rapidly gained a prominent
role as monotherapy as well as in combination with cytostatic
agents. A problem not yet solved is related to HER-2 evaluation,
an essential prerequisite to any application of trastuzumab.
Five-year view
In the near future, trastuzumab may also be approved for the
treatment of primary breast cancer and become a standard
therapy for all breast cancer patients with HER-2-overexpressing
tumors. The problem of invalid HER-2 diagnosis should be
overcome, either by new and easier to apply tests or by specialized
laboratories which provide complete HER-2 diagnostics.
Increased knowledge of tumor biology associated with HER-2
overexpression will enable better adjustment of all therapies for
high-risk breast cancers. More cancer-specific protein markers
will be identified and suitable antibodies tested in clinical trials.
This will bring us a big step forward in the road towards tailored
breast cancer therapy.
Figure 2. TECHNO trial design. Includes patients with HER2/neu 3+ or 2+ (depending on fluorescence in situ hybridization analysis result). 
Surgery
Epirubicin 90 mg/m2
Cyclophosphamide 600 mg/m2 
Paclitaxel 175 mg/m2
Trastuzumab 6 mg/kg
Every 3 weeks Every 3 weeks
Every 3 weeks 
for 36 weeks
Key issues
•  Approximately 25–30% of all breast cancer patients have tumors overexpressing the growth factor receptor HER-2.
•  Overexpression of HER-2 is associated with aggressive tumors and unfavorable prognosis.
•  HER-2 overexpression downregulates hormone receptor expression, thus rendering antihormonal therapy less efficient.
•  Trastuzumab is a monoclonal antibody interacting with and blocking the HER-2 protein.
•  Efficacy and tolerability of trastuzumab for the treatment of advanced breast cancer overexpressing HER-2 are well proven.
•  Cardiac toxicity of trastuzumab limits application, especially in combination with anthracyclines. Side effects are otherwise generally mild.
•  Trastuzumab has been approved for treatment of advanced breast cancer in the USA since 1998 and in Europe since 2000. Trials 
determining the effects of trastuzumab in primary breast cancer both before and after surgery are ongoing.
•  Trastuzumab already holds a prominent place in the treatment of metastatic breast cancer overexpressing HER-2, providing a therapy 
option complementary to surgery, radiation, chemotherapy and antihormonal therapy.
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